1. Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson’s disease
- Author
-
Kay Yaw Tay, Nicole C Keong, Ebonne Yulin Ng, Zheyu Xu, Samuel Yong-Ern Ng, Wing Lok Au, Eng-King Tan, Yi Jayne Tan, Nicole Shuang-Yu Chia, Fiona Setiawan, Adeline Su Lyn Ng, Louis C.S. Tan, and Zhonghao Lu
- Subjects
Male ,Nervous system ,Aging ,medicine.medical_specialty ,Parkinson's disease ,Ubiquitin C-Terminal Hydrolase ,Disease ,Motor Activity ,UCHL1 ,Severity of Illness Index ,Cognition ,Cerebrospinal fluid ,Ubiquitin ,blood ,Internal medicine ,ubiquitin ,Hydrolase ,medicine ,Humans ,Aged ,biology ,business.industry ,biomarkers ,Parkinson Disease ,Cell Biology ,Middle Aged ,Prognosis ,medicine.disease ,medicine.anatomical_structure ,Endocrinology ,Proteasome ,Parkinson’s disease ,biology.protein ,Female ,business ,Ubiquitin Thiolesterase ,Research Paper - Abstract
Parkinson’s disease (PD) is characterized by Lewy bodies containing α-synuclein and ubiquitin aggregates, their co-occurrence possibly linked to a failure of the ubiquitin proteasome system. Ubiquitin C-terminal hydrolase L1 (UCHL1) plays an important role in maintenance of nervous system integrity, and overexpression of UCHL1 has been shown to increase ubiquitin levels within neurons. While cerebrospinal fluid ubiquitin levels were reported to be lower in PD vs controls, plasma UCHL1 levels and their relationship with clinical measures in PD has not been reported. We measured plasma UCHL1 levels using single molecule array (Simoa) in 291 subjects (242 PD and 49 healthy controls, HC). We found that UCHL1 levels were significantly higher in PD patients at moderate stages (Hoehn and Yahr, H&Y stage >2) vs milder PD (H&Y ≤2, p
- Published
- 2020